Vertex Pharmaceuticals Incorporated
VRTX
$401.08
$0.920.23%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 3.62B | 3.47B | 3.36B | 3.26B | 3.32B |
| Total Depreciation and Amortization | 169.50M | 160.70M | 155.30M | 151.20M | 148.30M |
| Total Amortization of Deferred Charges | 11.80M | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.10M | 268.40M | 173.80M | 150.20M | 318.80M |
| Change in Net Operating Assets | -265.70M | 482.30M | 374.20M | 512.50M | 340.80M |
| Cash from Operations | 3.54B | 4.38B | 4.07B | 4.07B | 4.13B |
| Capital Expenditure | -200.40M | -175.90M | -189.50M | -183.20M | -204.70M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 0.00 | -295.90M | -295.90M | -295.90M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.94B | -1.90B | -1.86B | -1.62B | 179.50M |
| Cash from Investing | -3.14B | -2.08B | -2.35B | -2.10B | -321.10M |
| Total Debt Issued | 1.80M | 3.50M | 3.50M | 3.50M | 3.50M |
| Total Debt Repaid | -44.90M | -43.30M | -81.50M | -83.20M | -85.50M |
| Issuance of Common Stock | 134.60M | 139.80M | 161.00M | 166.80M | 186.30M |
| Repurchase of Common Stock | -653.70M | -503.10M | -380.90M | -353.90M | -172.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 900.00K | 500.00K | -200.00K | 0.00 |
| Cash from Financing | -562.20M | -402.20M | -297.40M | -267.00M | -67.70M |
| Foreign Exchange rate Adjustments | 26.90M | 40.30M | 24.60M | -11.30M | -29.20M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -139.70M | 1.94B | 1.45B | 1.69B | 3.71B |
